Текст книги "COVID-19/SARS-CoV-2"

950. Gauci ML, Coutzac C, Houot R, et al. FITC. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC). Eur J Cancer. 2021 May;148:121—123. doi: 10.1016/j. ejca.2021.02.003. Epub 2021 Feb 18. PMID: 33743480; PMCID: PMC7891073.

951. Lee YJ, Kim SE, Park YE, et al. Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases (KASID). SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID. Intest Res. 2022 Apr;20 (2):171—183. doi: 10.5217/ir.2021.00098. Epub 2022 Jan 5. PMID: 34974674; PMCID: PMC9081989.

952. Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, et al. COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. 2021 Apr;147:154—160. doi: 10.1016/j. ejca.2021.01.033. Epub 2021 Feb 10. PMID: 33676266; PMCID: PMC7874914.

953. G Di Lorenzo, R Di Trolio, Z Kozlakidis et al. Critical Reviews in Oncology/Hematology. Volume 152, August 2020, 102991. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. https://doi.org/10.1016/j.critrevonc.2020.102991.

954. NIH – Special Considerations in Adults and Children With Cancer. Last Updated: December 1, 2022. https://bit.ly/3MaUWHU. Дата посещения 20.02.23.

955. American Society of Hematology. General principles of COVID-19 vaccines for immunocompromised patients. 2022. Available at: https://www.hematology.org/covid-19/ash-astct-covid-19-and-vaccines. Accessed November 7, 2022.

956. American Society of Hematology. ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients: frequently asked questions. 2022. Available at: https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients. Accessed November 7, 2022.

957. National Comprehensive Cancer Network. Recommendations of the National Comprehensive Cancer Network (NCCN) Advisory Committee on COVID-19 vaccination and pre-exposure prophylaxis. 2022. Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v5-0.pdf?sfvrsn=b483da2b_80.

958. Mair MJ, Berger JM, Mitterer M, et al. Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study. Eur J Cancer. 2022;165:184—194. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35248840.

959. Yarza R, Bover M, Paredes D, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer. 2020;135:242—250. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32586724.

960. American Society of Clinical Oncology. Cancer treatment and supportive care. 2022. Available at: https://old-prod.asco.org/covid-resources/patient-care-info/cancer-treatment-supportive-care. Accessed November 17, 2022.

961. American Society of Hematology. COVID-19 and Hodgkin lymphoma: frequently asked questions. 2022. Available at: https://www.hematology.org/covid-19/covid-19-and-hodgkin-lymphoma. Accessed November 7, 2022.

962. Griffiths EA, Alwan LM, Bachiashvili K, et al. Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. J Natl Compr Canc Netw. 2020;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32871558.

963. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395 (10241):1919—1926. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32473682.

964. Yahalom J, Dabaja BS, Ricardi U, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020;135 (21):1829—1832. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32275740.

965. Zimmer AJ, Freifeld AG. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract. 2019;15 (1):19—24. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30629902.

966. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384 (8):693—704. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32678530.

967. Nawar T, Morjaria S, Kaltsas A, et al. Granulocyte-colony stimulating factor in COVID-19: is it stimulating more than just the bone marrow? Am J Hematol. 2020;95 (8):E210-E213. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32419212.

968. Sullivan M, Bouffet E, Rodriguez-Galindo C, et al. The COVID-19 pandemic: a rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. Pediatr Blood Cancer. 2020;67 (7):e28409. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32400924.

969. Bouffet E, Challinor J, Sullivan M, et al. Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. Pediatr Blood Cancer. 2020;67 (7):e28327. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32239747.

970. Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter initial guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc. 2020;9 (6):701—715. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32318706.